Minimal scarring in a premature neonate.

JPRAS Open

Division of Plastic, Reconstructive and Maxillo-Facial Surgery, The University of Cape Town, South Africa.

Published: December 2023

Background: Scar formation and management is one of the major issues in plastic surgery. Scars are a chronic burden to patients, their families, and the wider healthcare system and while non-surgical and surgical options have been shown to reduce scarring and its impact, there are currently no therapeutic options to completely heal scars or to avoid scarring. Early gestation animals have been reported to heal skin wounds without scarring.

Case Presentation: We report on a premature, underweight-for-age neonate of 30 weeks' gestation that suffered a combination of deep partial thickness abrasions and full thickness wounds following birth trauma, who eventually healed with minimal skin scarring.

Conclusion: This case highlights that more research is needed to understand the mechanism and timelines of foetal skin healing, so the knowledge can be used to develop better therapeutic options to treat skin scars in adults.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587665PMC
http://dx.doi.org/10.1016/j.jpra.2023.10.003DOI Listing

Publication Analysis

Top Keywords

therapeutic options
8
minimal scarring
4
scarring premature
4
premature neonate
4
neonate background
4
background scar
4
scar formation
4
formation management
4
management major
4
major issues
4

Similar Publications

Distal tibial fractures are common lower-limb injuries and are generally associated with a high risk of postoperative complications, especially in patients with multiple medical comorbidities. This study sought to ascertain the efficacy of retrograde intramedullary tibial nails (RTN) for treating extra-articular distal tibial fractures in high-risk patients. Between January 2019 and December 2021, 13 patients considered at high risk for postoperative complications underwent RTN fixation.

View Article and Find Full Text PDF

Wounds from gunshots and other explosive devices are a source of loss of substances directly or secondary to a well- conducted debridement. In addition, these types of wounds are by definition contaminated. The major challenge in this context for any surgeon remains coverage.

View Article and Find Full Text PDF

Background: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) exhibit a notably aggressive phenotype, which is associated with poor patient survival outcomes. These tumors are generally resistant to conventional cytotoxic chemotherapy, thereby limiting the availability of effective treatment options.

Case Presentation: We describe a 69-year-old AIDS patient who initially presented with a fused, enlarged lymph node on the right clavicle and mild, unexplained pain under the right axilla that worsened with severe coughing episodes.

View Article and Find Full Text PDF

Claudin 18.2: An attractive marker in pancreatic ductal adenocarcinoma.

Oncol Lett

March 2025

Department of Pathology, National Institute of Gastroenterology, IRCCS 'S. de Bellis' Research Hospital, Castellana Grotte, I-70013 Bari, Italy.

Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive tumor with limited treatment options. Zolbetuximab, a monoclonal antibody against the tight junction protein Claudin 18.2 has recently been developed.

View Article and Find Full Text PDF

Introduction: Treatment of type 2 diabetes (T2D) remains a significant challenge because of its multifactorial nature and complex metabolic pathways. There is growing interest in finding new therapeutic targets that could lead to safer and more effective treatment options. Takeda G protein-coupled receptor 5 (TGR5) is a promising antidiabetic target that plays a key role in metabolic regulation, especially in glucose homeostasis and energy expenditure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!